1h Free Analyst Time
The anti-CD20 monoclonal antibodies (MABs) market is forecasted to grow by USD 15.64 billion during 2024-2029, accelerating at a CAGR of 12.3% during the forecast period. The report on the anti-CD20 monoclonal antibodies (MABs) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increased use of combination therapies, high target affinity and specificity of anti-CD20 MABs, and strong pipeline and recent approvals.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The anti-CD20 monoclonal antibodies (MABs) market is segmented as below:
By Product
- Oncology
- Neurology
- Immunology
By Type
- First generation
- Second generation
- Third generation
By End-user
- Hospitals and clinics
- Academic and research institutions
- Contract research organizations
By Drug Class
- Rituximab
- Ofatumumab
- Obinutuzumab
- Ublituximab
- Others
By Route Of Administration
- Intravenous
- Subcutaneous
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the anti-CD20 monoclonal antibodies (MABs) market covers the following areas:
- Anti-CD20 Monoclonal Antibodies (MABs) Market sizing
- Anti-CD20 Monoclonal Antibodies (MABs) Market forecast
- Anti-CD20 Monoclonal Antibodies (MABs) Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Product
9 Market Segmentation by Type
10 Market Segmentation by End-user
11 Market Segmentation by Drug Class
12 Market Segmentation by Route of Administration
13 Customer Landscape
14 Geographic Landscape
15 Drivers, Challenges, and Opportunity/Restraints
16 Competitive Landscape
17 Competitive Analysis
18 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global anti-CD20 monoclonal antibodies (MABs) market: Acrotech Biopharma Inc., Amgen Inc., AstraZeneca PLC, Celltrion Healthcare Co. Ltd., F. Hoffmann La Roche Ltd., Fosun International Ltd., Genmab AS, IGM Biosciences Inc., JSC BIOCAD, LFB SA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Spectrum Pharmaceuticals Inc., TG Therapeutics Inc., United BioPharma Inc., and ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing awareness about therapeutic areas."
According to the report, one of the major drivers for this market is the increased use of combination therapies.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acrotech Biopharma Inc.
- Amgen Inc.
- AstraZeneca Plc
- Celltrion Healthcare Co. Ltd.
- F. Hoffmann La Roche Ltd.
- Fosun International Ltd.
- Genmab AS
- IGM Biosciences Inc.
- JSC BIOCAD
- LFB SA
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Spectrum Pharmaceuticals Inc.
- TG Therapeutics Inc.
- United BioPharma Inc.
- ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd.
